Seth Lederman compensation by year
Tonix Pharmaceuticals Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $472,500 | $472,500 | $585,000 | $614,250 | $675,000 | $675,000 | $675,000 | $675,000 | $702,000 |
| Bonus | $0 | $160,000 | $198,095 | $460,688 | $506,250 | $355,000 | $0 | $417,656 | $596,700 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 |
| Option awards | $103,344 | $844,945 | $505,178 | $2,799,884 | $6,527,139 | $3,550,167 | $1,375,065 | $717,111 | $1,870,130 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 |
| All other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 |
| Total | $575,844 | $1,477,445 | $1,288,273 | $3,874,822 | $7,708,389 | $4,580,167 | $2,050,065 | $1,809,767 | $3,168,830 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tonix Pharmaceuticals Holding Corp. DEF 14A filed March 30, 2026, accession 0001999371-26-007108, and prior-year filings.
How this page was built: the Tonix Pharmaceuticals Holding Corp. filed document, accession 0001999371-26-007108. Every figure is read from that document and cited to the page and table it appears in. Filed March 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 123,958 | — | $10.06 |
| Option | 123,958 | — | $8.05 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Tonix Pharmaceuticals Holding Corp.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Tonix Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Seth Lederman · this page | Chief Executive Officer | $3,168,830 |
| Jessica Morris | Chief Operations Officer | $1,226,269 |
| Gregory Sullivan | Chief Medical Officer | $1,216,542 |
| Bradley Saenger | Chief Financial Officer | $1,143,513 |
Board service
Tonix Pharmaceuticals board · FY2021–FY2025How this board is paid
Company policy: Tonix Pharmaceuticals pays directors a $55,000 cash retainer and $188,830 in Options. As stated in Tonix Pharmaceuticals's FY2025 proxy.
The full Tonix Pharmaceuticals compensation record
free company briefThis page is one person within Tonix Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Tonix Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tonix Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.